IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 304 filers reported holding IONIS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $15,727,537 | +103.5% | 346,727 | +84.1% | 0.00% | +50.0% |
Q2 2023 | $7,728,903 | -48.8% | 188,372 | -55.4% | 0.00% | -33.3% |
Q1 2023 | $15,085,783 | -57.8% | 422,098 | -55.4% | 0.00% | -62.5% |
Q4 2022 | $35,783,713 | -37.3% | 947,411 | -26.6% | 0.01% | -38.5% |
Q3 2022 | $57,081,000 | +48.0% | 1,290,565 | +23.9% | 0.01% | +44.4% |
Q2 2022 | $38,569,000 | +9.1% | 1,041,824 | +9.2% | 0.01% | +28.6% |
Q1 2022 | $35,348,000 | +97.1% | 954,326 | +61.9% | 0.01% | +75.0% |
Q4 2021 | $17,933,000 | -11.2% | 589,298 | -2.1% | 0.00% | 0.0% |
Q3 2021 | $20,186,000 | -25.5% | 601,836 | -11.4% | 0.00% | -33.3% |
Q2 2021 | $27,102,000 | -19.1% | 679,429 | -8.8% | 0.01% | -25.0% |
Q1 2021 | $33,491,000 | -43.3% | 744,910 | -28.7% | 0.01% | -46.7% |
Q4 2020 | $59,030,000 | +110.8% | 1,044,054 | +76.9% | 0.02% | +87.5% |
Q3 2020 | $27,998,000 | -37.8% | 590,060 | -22.7% | 0.01% | -42.9% |
Q2 2020 | $45,032,000 | +25.4% | 763,778 | +0.5% | 0.01% | +16.7% |
Q1 2020 | $35,922,000 | +11.1% | 759,750 | +42.0% | 0.01% | +50.0% |
Q4 2019 | $32,321,000 | -5.4% | 535,026 | -6.2% | 0.01% | -20.0% |
Q3 2019 | $34,162,000 | -69.4% | 570,229 | -67.2% | 0.01% | -69.7% |
Q2 2019 | $111,770,000 | +179.9% | 1,739,075 | +253.6% | 0.03% | +175.0% |
Q1 2019 | $39,926,000 | -38.9% | 491,876 | -59.3% | 0.01% | -40.0% |
Q4 2018 | $65,394,000 | -23.9% | 1,209,652 | -27.4% | 0.02% | -9.1% |
Q3 2018 | $85,885,000 | +22.0% | 1,665,075 | -1.4% | 0.02% | +15.8% |
Q2 2018 | $70,378,000 | -19.4% | 1,688,923 | -14.7% | 0.02% | -13.6% |
Q1 2018 | $87,273,000 | -13.7% | 1,979,867 | -1.5% | 0.02% | -8.3% |
Q4 2017 | $101,154,000 | +11.7% | 2,010,998 | +12.6% | 0.02% | +9.1% |
Q3 2017 | $90,558,000 | +15.6% | 1,786,157 | +15.9% | 0.02% | +15.8% |
Q2 2017 | $78,367,000 | +164.5% | 1,540,536 | +109.0% | 0.02% | +137.5% |
Q1 2017 | $29,627,000 | -10.6% | 736,989 | +6.4% | 0.01% | -11.1% |
Q4 2016 | $33,128,000 | -21.4% | 692,617 | -39.8% | 0.01% | -30.8% |
Q3 2016 | $42,141,000 | +32.4% | 1,150,138 | -15.8% | 0.01% | +18.2% |
Q2 2016 | $31,818,000 | -2.7% | 1,366,206 | +69.2% | 0.01% | 0.0% |
Q1 2016 | $32,698,000 | -69.1% | 807,323 | -52.7% | 0.01% | -66.7% |
Q4 2015 | $105,742,000 | – | 1,707,432 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BB BIOTECH AG | 6,529,838 | $404,393,000 | 11.39% |
DOWLING & YAHNKE LLC | 676,379 | $41,888,000 | 5.27% |
Opus Point Partners Management, LLC | 102,459 | $6,345,000 | 4.19% |
WILLIAM HARRIS INVESTORS INC | 230,443 | $14,271,000 | 3.43% |
PINNACLE ASSOCIATES LTD | 1,690,263 | $104,678,000 | 2.20% |
MESSNER & SMITH THEME VALUE INVESTMENT MANAGEMENT LTD /CA/ | 21,298 | $1,319,000 | 2.11% |
Sonora Investment Management, LLC | 126,763 | $7,850,000 | 2.04% |
Virtus ETF Advisers LLC | 10,447 | $647,000 | 1.78% |
Apex Capital Management | 1,020,096 | $63,175,000 | 1.41% |
PERKINS CAPITAL MANAGEMENT INC | 19,900 | $1,232,000 | 1.32% |